Molecular Biology Research Communications (MBRC) is an international pree-reviewed journal. It is published quarterly by Shiraz University. The journal welcomes submission of Original articles, Short communications, Invited review articles, and Letters to the Editor which meets the general criteria of significance and scientific excellence in all fields of molecular biology. The journal's short title is Mol. Biol. Res. Commun., which should be used in bibliographies, footnotes and bibliographical references and strips.

 

The key of success is commitment to excellence. The journal celebrates its recent recognition by the Scopus, "Institute for Scientific Information (ISI, Emerging Sources Citation Index) Thomson Reuters" and Pubmed as a step of achieving excellence and beyond. Congratulation to all contributors including authors and reviewers.

 

Open Access Policy

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.

What are some advantages of publishing your work in MBRC?

- Free access for all users worldwide

- First decision within 6-8 weeks of submission

- Prompt and fair peer review from two expert peer reviewers

- Frequent updates on your paper’s status

- Friendly responsive staff

- Increased visibility and readership of your papers

- No page charge

                         

Frequency

Molecular Biology Research Communications is published quarterly in the following months; March, June, September, and December.  

 

Rejection rate: 66%                                                       

Current Issue: Volume 10, Issue 3, September 2021 

2. Role of SALL4 and Nodal in the prognosis and tamoxifen resistance of estrogen receptor-positive breast cancer

Pages 109-119

10.22099/mbrc.2021.39878.1597

Arad Boustan; Fatemeh Mosaffa; Rosa Jahangiri; Hamid Heidarian-Miri; Asefeh Dahmardeh-Ghalehno; Khadijeh Jamialahmadi


3. Telomeric zinc-finger associated protein (TZAP) in cancer biology: friend or foe?

Pages 121-129

10.22099/mbrc.2021.40106.1607

Gabriel Arantes dos Santos; Nayara Izabel Viana; Ruan Pimenta; Juliana Alves de Camargo; Sabrina T. Reis; Katia Ramos Moreira Leite; Miguel Srougi


4. In silico identification of promising inhibitor against RNA-dependent RNA polymerase target of SARS-CoV-2

Pages 131-140

10.22099/mbrc.2021.40367.1621

Pushpendra Singh; Manish Kumar Tripathi; Mohammad Yasir; Ruchi Khare; Rahul Shrivastava


5. MiR-200c-3p expression may be associated with worsening of the clinical course of patients with COVID-19

Pages 141-147

10.22099/mbrc.2021.40555.1631

Ruan Pimenta; Nayara I Viana; Gabriel A dos Santos; Patricia Candido; Vanessa R Guimaraes; Poliana Romao; Iran A Silva; Juliana A de Camargo; Dina M Hatanaka; Paula G S Queiroz; Alexandre Teruya; Leandro Echenique; Bruno A M P Besen; Katia R M Leite; Victor Srougi; Miguel Srougi; Sabrina T Reis